The designation was based on Phase Ib data that showed significant early signs of antitumor activity in some patients with aggressive cases of the deadly skin cancer.
GE Healthcare's PET imaging agent designed to help spot Alzheimer's disease drew in another international drug company partner developing a treatment in the space.
Alleged links between vaccines and the nerve-degenerative disorder Guillain-Barré are among vaccine safety fears. A new study shows that any link between them is not strong enough to outweigh the benefits of vaccines.
Researchers at the University of Rochester Medical Center have developed a way to make a well-known breast cancer drug more effective against aggressive forms of the disease by altering slightly the treatment's target mechanism.
To combat pancreatic cancer, notable for its staunch resistance to many treatments, researchers at the Albert Einstein College of Medicine in New York's Yeshiva University have turned to living bacteria that can deliver radioactivity directly to tumor cells.
Researchers at Northeastern University have developed a treatment for Parkinson's disease meant to revive dying neurons in the brain via delivery through the nose.
Roche today said that its Applied Science Business Area will be dissolved and its portfolio of products integrated within Roche's other diagnostics business areas--a move that will affect 110 positions in Penzberg, Germany, and 60 positions in Branford, CT.
While the success rate in developing new disease treatments remains alarmingly low, a cadre of R&D executives from some of the world's biggest drug developers insisted at BIO that they've zeroed in on a number of ways to boost the chance a promising drug will actually reach patients.
The city of Chicago is hoping to take advantage of the spotlight of the annual BIO convention to build up its biotech cred a little. City officials later today are expected to announce plans to set up an incubator and research and collaboration hub in the downtown area.
After delivering data from multiple rounds of trials on all-oral combos against hepatitis C, pharma runners appear to be making progress with new therapies that could shorten treatment durations and wipe out the liver-damaging virus without infusions of interferon and the flulike side effects that go with them.